Market Intel: Virtual Reality: The New Game In Mental Health Care To Improve Outcomes

Virtual reality is seeing an upsurge in use by mental health practitioners for treating conditions such as post-traumatic stress disorder, panic disorders and anxiety in a safe and controlled manner. With the advent of affordable VR headsets and technological advances, companies and researchers worldwide are seizing on the opportunity to bring such techniques as VR exposure therapy and cognitive behavioral therapy to telemedicine, specialty clinics and directly to consumers to improve outcomes and better lives.

MT1706_Market Intelligence_1200x675

A growing number of researchers and companies worldwide are exploring the power of virtual reality (VR) and gaming technologies for developing innovative solutions to help clinicians diagnose, treat and manage some of the most challenging behavioral conditions. Researchers believe that the use of VR technologies is rising for health care applications, fueled largely by technological innovations, such as the Oculus Rift headset, which are making VR therapies more affordable. This article takes a closer look at how VR is being used for exposure therapy at the U.S. Department of Veterans Affairs to help soldiers recover from post-traumatic stress disorder (PTSD), for cognitive behavioral therapy at Akili Interactive Labs Inc., which plans to file for US FDA approval for its Project: Echo to treat pediatric attention-deficit hyperactivity disorder (ADHD) and by researchers in the Netherlands to prevent relapse in patients recovering from mental illness. We'll also address limiters and growth opportunities and other projects in the works in this trending space.

One of the most promising and widely used VR technologies today is an interactive VR-based exposure therapy tool to assess...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Neurology

More from Device Area

  • Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

     

    Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

  • Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

     

    An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

  • TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

     

    TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.